Group 1 - The core viewpoint of the article highlights the significant stock price increase of 基石药业-B (02616), which rose over 5% following a substantial investment by the Singapore government investment company (GIC) [1] - As of the latest report, the stock price reached 10.7 HKD with a trading volume of 301 million HKD [1] - GIC increased its holdings by acquiring 80.4 million shares at an average price of 7.9 HKD per share, totaling approximately 635 million HKD, raising its ownership from 0.00% to 5.49% [1] Group 2 - The company continues to implement strategic collaborations, with a new indication application for舒格利单抗 planned for submission to the European Medicines Agency (EMA) by March 2025 [1] - In January 2025, the company established a commercialization strategic partnership with SteinCares for 10 Latin American countries, and in July 2025, it partnered with Gentili for 23 countries in Western Europe and the UK [1] - The international influence of舒格利单抗 has expanded to over 60 countries globally [1]
港股异动 | 基石药业-B(02616)再涨超5% GIC近期增持股份 公司战略合作持续落地